LAIV Composition & Replication

FLUMIST QUADRIVALENT expresses the same surface antigens as the influenza virus1,2

FLUMIST QUADRIVALENT expresses the same surface antigens as the influenza virus1,2

The vaccine virus strains express the surface proteins of hemagglutinin (HA) and neuraminidase (NA) from the wild-type viruses identified by the WHO that are expected to circulate during the season1-3

  • HA is responsible for the binding of the influenza virus to the host cell that it is infecting1,2
  • NA allows the release of newly developed virions (virus particles) from the host cell1,2
cell structure cell structure

With at least 5 attenuating points in each strain of FLUMIST vaccine, the odds of reversion to wild-type influenza are approximately 1 in 100 quintillion replication cycles (1x1020 replication cycles), more than a millennium in time5

FLUMIST QUADRIVALENT is a live attenuated influenza vaccine, engineered to stimulate an immune response and prevent flu1,6-8

  • Replicates in the nose to induce a broad immune response that closely resembles natural immunity4
human virus human virus

FLUMIST QUADRIVALENT is a live attenuated vaccine.1 Other routinely administered live attenuated vaccines include those for MMR, varicella, and rotavirus.9

IMPORTANT SAFETY INFORMATION


  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist
  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons
  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.